Back to Search
Start Over
Identification and characterization of RSIY-11, a novel seminal peptide derived from semenogelin-1, which acts as a neutral endopeptidase inhibitor modulating sperm motility
- Source :
- J Assist Reprod Genet
- Publication Year :
- 2019
-
Abstract
- PURPOSE: Based on prior reports demonstrating that neutral endopeptidase (NEP) inhibitors increase sperm motility, the goal of our studies was to identify endogenous seminal peptides that inhibit NEP and investigate their potential effect on sperm motility. METHODS: Peptidomic analysis was performed on human seminal fluid, identifying 22 novel peptides. One peptide, named RSIY-11, derived from semenogelin-1, was predicted through sequence analysis to be a substrate and/or potential inhibitor of NEP. Enzymatic analysis was conducted to determine the inhibitory constant (Ki) of RSIY-11 as an inhibitor of NEP. Total and progressive sperm motility was determined at baseline and 30 and 60 min following addition of RSIY-11 to seminal fluid in 59 patients undergoing an infertility workup at an urban medical center. Additionally, the effects of RSIY-11 on sperm motility were evaluated in 15 of the 59 patients that met criteria for asthenospermia. RESULTS: RSIY-11 was shown to act as a competitive inhibitor of NEP with a Ki of 18.4 ± 1.6 μM. Addition of RSIY-11 at concentrations of 0.75 μM, 7.5 μM, and 75 μM significantly increased sperm motility at all time points investigated, with increases of 6.1%, 6.9%, and 9.2% at 60 min, respectively. Additionally, within the subgroup of patients with asthenospermia, RSIY-11 at concentrations of 0.75 μM, 7.5 μM, and 75 μM significantly increased sperm motility at all time points investigated, with increases of 7.6%, 8.8%, and 10.6% at 60 min, respectively. CONCLUSIONS: RSIY-11 is a newly identified semenogelin-1-derived peptide present in seminal fluid. RSIY-11 acts as a potent competitive inhibitor of NEP, which when added to seminal fluid significantly increases sperm motility. RSIY-11 could play a potential role in the treatment for male factor infertility related to asthenospermia and improve intrauterine insemination outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10815-019-01524-8) contains supplementary material, which is available to authorized users.
- Subjects :
- 0301 basic medicine
Infertility
Adult
Male
Peptide
Endogeny
Inhibitory postsynaptic potential
Seminal Vesicle Secretory Proteins
Andrology
03 medical and health sciences
0302 clinical medicine
Semen
Gamete Biology
Genetics
medicine
Humans
Salivary Proteins and Peptides
Neprilysin
Genetics (clinical)
Sperm motility
Infertility, Male
chemistry.chemical_classification
030219 obstetrics & reproductive medicine
Dose-Response Relationship, Drug
Chemistry
Obstetrics and Gynecology
General Medicine
medicine.disease
Peptide Fragments
030104 developmental biology
Enzyme
Reproductive Medicine
Sperm Motility
Oligopeptides
Semenogelin
Developmental Biology
Subjects
Details
- ISSN :
- 15737330
- Volume :
- 36
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- Journal of assisted reproduction and genetics
- Accession number :
- edsair.doi.dedup.....b330851abc6162a1bdddeeb6c00d9285